Related Experiment Video
Updated: Aug 6, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Outcomes of Early Rhythm Control Therapy in Patients With Atrial Fibrillation and a High Comorbidity Burden in Large
Jannis Dickow1,2, Shinwan Kany1,2,3, Victor Roth Cardoso4,5
1Department of Cardiology, University Heart and Vascular Center Hamburg, University Hospital Hamburg Eppendorf (J.D., S.K., P.K., A.M., A.R.).
Insights
Early rhythm control (ERC) for atrial fibrillation significantly reduces adverse outcomes in patients with high comorbidity burden. This strategy is safe and particularly beneficial for those with a CHA2DS2-VASc score of 4 or higher.
Area of Science:
- Cardiology
- Clinical Trials
- Epidemiology
Background:
- Atrial fibrillation (AF) management strategies are evolving.
- Early rhythm control (ERC) shows potential benefits, particularly in specific patient subgroups.
- Previous studies suggest a possible differential effect of ERC based on patient comorbidity burden.
Purpose of the Study:
- To evaluate the effectiveness and safety of early rhythm control (ERC) in patients with atrial fibrillation (AF).
- To compare outcomes between patients with high versus lower comorbidity burden receiving ERC.
- To assess the interaction between comorbidity burden and ERC treatment efficacy.
Main Methods:
- Retrospective analysis of two large cohorts: OptumLabs (US claims database) and UK Biobank (UK population-based data).
- Identified 109,739 (OptumLabs) and 11,625 (UKB) patients with newly diagnosed AF.
- Defined ERC as AF ablation or antiarrhythmic drug therapy within one year of diagnosis; stratified patients by ERC use and CHA2DS2-VASc score (high ≥4, lower 2-3).
- Used propensity score overlap weighting and Cox regression to compare composite outcomes (mortality, stroke, HF/MI hospitalization) and safety outcomes.
Main Results:
- ERC significantly reduced the primary composite outcome in patients with high comorbidity burden (OptumLabs HR 0.83, UKB HR 0.77).
- No significant difference in outcomes was observed for patients with lower comorbidity burden (OptumLabs HR 0.92, UKB HR 0.94).
- A significant interaction between comorbidity burden and ERC benefit was found in the UKB cohort (P=0.027). ERC was safe, with no increased risk of adverse events.
Conclusions:
- Early rhythm control (ERC) is a safe and effective strategy for managing atrial fibrillation.
- ERC demonstrates a more favorable outcome profile in patients with a high comorbidity burden (CHA2DS2-VASc score ≥4).
- These findings support tailoring rhythm control strategies based on individual patient risk profiles.
Background:
A recent subanalysis of the EAST-AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial) suggests a stronger benefit of early rhythm control (ERC) in patients with atrial fibrillation and a high comorbidity burden when compared to patients with a lower comorbidity burden.
Methods:
We identified 109 739 patients with newly diagnosed atrial fibrillation in a large United States deidentified administrative claims database (OptumLabs) and 11 625 patients in the population-based UKB (UK Biobank). ERC was defined as atrial fibrillation ablation or antiarrhythmic drug therapy within the first year after atrial fibrillation diagnosis. Patients were classified as (1) ERC and high comorbidity burden (CHA2DS2-VASc score ≥4); (2) ERC and lower comorbidity burden (CHA2DS2-VASc score 2-3); (3) no ERC and high comorbidity burden; and (4) no ERC and lower comorbidity burden. Patients without an elevated comorbidity burden (CHA2DS2-VASc score 0-1) were excluded. Propensity score overlap weighting and cox proportional hazards regression were used to balance patients and compare groups for the primary composite outcome of all-cause mortality, stroke, or hospitalization with the diagnoses heart failure or myocardial infarction as well as for a primary composite safety outcome of death, stroke, and serious adverse events related to ERC.
Results:
In both cohorts, ERC was associated with a reduced risk for the primary composite outcome in patients with a high comorbidity burden (OptumLabs: hazard ratio, 0.83 [95% CI 0.72-0.95]; P=0.006; UKB: hazard ratio, 0.77 [95% CI, 0.63-0.94]; P=0.009). In patients with a lower comorbidity burden, the difference in outcomes was not significant (OptumLabs: hazard ratio, 0.92 [95% CI, 0.54-1.57]; P=0.767; UKB: hazard ratio, 0.94 [95% CI, 0.83-1.06]; P=0.310). The comorbidity burden interacted with ERC in the UKB (interaction- P=0.027) but not in OptumLabs (interaction-P=0.720). ERC was not associated with an increased risk for the primary safety outcome.
Conclusions:
ERC is safe and may be more favorable in a population-based sample of patients with high a comorbidity burden (CHA2DS2-VASc score ≥4).
More Related Videos
Related Concept Videos
01:29Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
01:25Dysrhythmias VI: Management of Dysrhythmias
01:25Dysrhythmias VII: Nursing Management of Dysrhythmias
01:30Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
01:21Rheumatic Heart Disease III: Medical Management
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias